Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldenberg, David M., Cardillo, Thomas M., Govindan, Serengulam V., Rossi, Edmund A., Sharkey, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673178/
https://www.ncbi.nlm.nih.gov/pubmed/26101915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673178/
https://www.ncbi.nlm.nih.gov/pubmed/26101915

Ejemplares similares